News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Perrigo Co. (PRGO) Mum On Published Merger Rumors, Potential Target For Abbott Laboratories (ABT)



7/17/2014 7:58:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Free from an underperforming unit, Abbott Laboratories (ABT) is positioned to go after potential targets from Insulet Corp. to Perrigo (PRGO) Co.

Abbott said this week that it’s selling part of its generic drug business to Mylan Inc. in exchange for a 21 percent stake in the new entity, which will be based in the Netherlands for tax advantages. Abbott, which could get about $5 billion when it cashes out of that stake, may seek deals that would bolster its medical-device business. The $62 billion company could expand its presence in the diabetes market by buying Insulet or Tandem (TNDM) Diabetes Care Inc., said Leerink Partners LLC, which also sees diagnostic-equipment maker Volcano (VOLC) Corp. as a target.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES